<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000725.v1.p1" parentStudy="phs000725.v1.p1" createDate="2014-03-11" modDate="2015-03-16">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>David A. Wheeler, PhD</td><td>Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA</td></tr>
		<tr><td>Funding Source</td><td>5U54HG003273</td><td>National Human Genome Research Institute (NHGRI), Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Rare Cancer Tumors Project</StudyNameEntrez>
	<StudyNameReportPage>Rare Cancer Tumors Project</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Cohort</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>A large proportion of common cancers affecting patients around the world have been selected for comprehensive cancer genome studies. Further efforts will be needed to tackle the remaining tumor types, including the rare forms of cancers. Although rare, these cancers tend to be more aggressive and fast growing with an early recurrence following initial chemotherapy and poor prognosis. Besides, patients diagnosed with rare cancers may have difficulty finding a physician knowledgeable in treating their type of cancer. While sample collection is a major challenge, the integrated genomic analyses would identify novel causative genes in these rare cancers, shed new light on the biology of the rare cancers, as well as guide novel targeted cancer therapies. Through efficient collaboration, the Human Genome Sequencing Center (HGSC) at Baylor College of Medicine (BCM) has collected/is expected to collect 20 different types of rare cancers, 15-30 cases each. Whole-exome sequencing and high-resolution SNP array analysis were/will be performed for all cases and whole-genome sequencing was designed for a selected subset of the cases.</p> <p><b>The Rare Cancer Tumors Cohort is utilized in the following dbGaP sub-studies.</b> To view genotypes, other molecular data, and derived variables collected in this sub-study, please click on the following sub-study below or in the "Sub-studies" box located on the right hand side of this top-level study page <a href="./study.cgi?study_id=phs000725">phs000725</a> Rare Cancer Tumors Cohort. <ul> <li><a href="./study.cgi?study_id=phs000754">phs000754</a> Intracranial Germ Cell Tumors</li> <li><a href="./study.cgi?study_id=phs000861">phs000861</a> Craniopharyngioma Tumors</li> <li><a href="./study.cgi?study_id=phs000859">phs000859</a> Sezary Syndrome Genomic Analysis</li> </ul> </p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Patient Inclusion Criteria: with informative pathological diagnosis, good DNA quality and quantity.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Neoplasms"/>
		<Disease vocab_source="MESH" vocab_term="Brain Neoplasms"/>
		<Disease vocab_source="MESH" vocab_term="Germinoma"/>
		<Disease vocab_source="MESH" vocab_term="Neoplasms, Germ Cell and Embryonal"/>
		<Disease vocab_source="MESH" vocab_term="Endodermal Sinus Tumor"/>
		<Disease vocab_source="MESH" vocab_term="Teratoma"/>
		<Disease vocab_source="MESH" vocab_term="Carcinoma, Embryonal"/>
		<Disease vocab_source="MESH" vocab_term="Choriocarcinoma"/>
		<Disease vocab_source="MESH" vocab_term="Polycythemia Vera"/>
		<Disease vocab_source="MESH" vocab_term="Craniopharyngioma"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>David A. Wheeler, PhD</AttName>
			<Institution>Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>5U54HG003273</AttName>
			<Institution>National Human Genome Research Institute (NHGRI), Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000725.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000725.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000725.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
